Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 2INDUSTRY 2NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Lymphoma 4Breast Neoplasms 4Sarcoma 3Rhabdomyosarcoma 2Ovarian Neoplasms 2Lymphoma, Large B-Cell, Diffuse 2Lung Neoplasms 2Inflammatory Breast Neoplasms 2Fallopian Tube Neoplasms 2Carcinoma 2Teratoma 1Sarcoma, Synovial 1Recurrent Uterine Corpus Sarcoma 1Recurrent Uterine Corpus Carcinoma 1Pancreatic Neoplasms 1Neutropenia 1Neurofibrosarcoma 1Malignant mesenchymal tumor 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Follicular 1Liposarcoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Leiomyosarcoma 1Kidney Neoplasms 1Hodgkin Disease 1Histiocytoma, Malignant Fibrous 1Hemangiosarcoma 1Fibrosarcoma 1Esophageal Squamous Cell Carcinoma 1

Interventions

Paclitaxel 20Carboplatin 18Cisplatin 12Topotecan 6Docetaxel 5Gemcitabine 4Etoposide 3rubitecan 2Taxes 2Surgical Procedures, Operative 2Filgrastim 2Erlotinib Hydrochloride 2Cyclophosphamide 2vandetanib 1sargramostim 1pegfilgrastim 1motesanib diphosphate 1liposomal doxorubicin 1liposomal amphotericin B 1Watchful Waiting 1Vorinostat 1Trabectedin 1Polymerase Chain Reaction 1Peripheral Blood Stem Cell Transplantation 1Pemetrexed 1Ondansetron 1Neoadjuvant Therapy 1Mitoxantrone 1Mifepristone 1Mass Spectrometry 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Carcinoma, Ovarian Epithelial × pegfilgrastim × Clear all
NCT00569673 2018-07-18

Docetaxel, Trabectedin, and G-CSF or Pegfilgrastim in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer

GOG Foundation

Phase 2 Completed
71 enrolled 8 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡